Warby Parker, Google To Launch Ai-Powered Smart Glasses In 2026

Investing.com -- The supermarket sector continues to offer investors a mix of stability, growth, and value opportunities as we move into 2026. According to WarrenAI analysis using Investing Pro’s metrics, several key players stand out in this defensive yet evolving industry. Here’s a breakdown of the top performers based on fair value, analyst targets, and financial health.

Kroger leads the pack as the most balanced supermarket investment, while specialty retailers and value players round out the list. Each company presents unique strengths and challenges for investors seeking exposure to this essential retail segment.

1. Kroger Co. (NYSE:KR)

Kroger maintains its position as a core supermarket investment for 2025, supported by a solid "good performance" Pro score and positive 8.0% 12-month return. Analyst targets suggest approximately 16% potential upside from current levels, with technicals showing a neutral-to-cautiously-bullish stance on shorter timeframes. The company recently beat earnings expectations, and ongoing cost-cutting measures, including closing Ocado warehouses, could support margins. However, investors should note Kroger’s substantial debt/equity ratio of 302.7%, which may become problematic if interest rates rise.

Want more top stock picks and analysis? Use WarrenAI by upgrading to InvestingPro - get 55% off today

2. Sprouts Farmers Market (NASDAQ:SFM)

Sprouts boasts the highest Pro Score among the group and impressive double-digit revenue growth (13.1% in the latest quarter). Analyst targets imply a substantial 48% upside potential. However, technical indicators warn of persistent weakness, showing strong sell signals across most timeframes. The stock’s -43.4% one-year return reflects both execution challenges and high expectations built into its premium valuation (P/E 36.2x). Sprouts represents an opportunity for aggressive investors betting on health and wellness trends, though volatility and competitive pressures remain concerns.

3. Albertsons Companies (NYSE:ACI)

Albertsons presents as a value play, trading below fair value while offering a 2.9% dividend yield. The company is advancing its technological capabilities with initiatives like its AI shopping assistant launch. However, technical indicators remain weak, showing strong sell signals across all timeframes, and the stock has delivered a negative one-year return. With the highest debt/equity ratio in the group at 418.9%, balance sheet risk requires monitoring. Future upside depends on successful business transformation and effective competition management.

4. Weis Markets (NYSE:WMK)

Weis Markets stands out as a conservative, under-the-radar option with minimal leverage (debt/equity 12%) and a strong current ratio (2.5x). The stock offers a modest 2.0% yield but has underperformed with a -4.1% one-year return and limited growth. Fair value calculations suggest 19.5% upside potential, indicating possible mean reversion opportunity. Current technical indicators remain bearish, suggesting patient investors may want to wait for trend reversal signals before establishing positions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Warby Parker Inc. (NYSE:WRBY) stock soared 12% Monday following the announcement of a partnership with Google to develop AI-powered glasses expected to launch in 2026.

The eyewear company revealed the collaboration during "The Android Show | XR Edition," where both companies disclosed plans to create lightweight, AI-enabled glasses. This marks a significant move for Warby Parker into the growing market for smart eyewear technology.

The partnership combines Warby Parker’s expertise in eyewear design and retail with Google’s technological capabilities in artificial intelligence and extended reality. While specific details about the glasses’ features remain limited, the announcement positions Warby Parker in the expanding field of AI-enhanced wearable technology.

Investors responded positively to the news, driving the stock’s double-digit percentage gain during Monday’s trading session.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Ocular Therapeutix Inc. (NASDAQ:OCUL) stock surged 29% Monday after the company announced plans to accelerate its New Drug Application (NDA) submission for AXPAXLI in wet age-related macular degeneration (AMD).

The biopharmaceutical company intends to submit its NDA shortly after receiving year one data from its Phase 3 SOL-1 clinical trial, assuming positive results, which are expected in the first quarter of 2026. This accelerated timeline comes after recent statements from FDA leadership suggesting a potential shift toward requiring only a single registrational trial for approval.

Ocular plans to leverage the 505(b)(2) regulatory pathway, which could potentially shorten the review timeline for AXPAXLI. The company highlighted that its SOL-1 trial is the only ongoing Phase 3 retina trial being conducted under a Special Protocol Assessment agreement with the FDA.

"At Ocular Therapeutix, we have always been courageous, opportunistic, and bold in our efforts to redefine retina," said Pravin U. Dugel, Executive Chairman, President and CEO of Ocular Therapeutix. "Based on recent developments, we now intend to submit our NDA for AXPAXLI in wet AMD shortly after SOL-1 year one data, assuming positive results."

If approved, AXPAXLI could become the first tyrosine kinase inhibitor (TKI) to be commercialized for wet AMD. The company is positioning the treatment as potentially superior to existing options, with dosing intervals that could extend to 6-12 months compared to the more frequent injections required by current therapies.

Wet AMD affects approximately 1.8 million people in the United States and 14.5 million globally. Despite advances in treatment, up to 40% of patients discontinue therapy within the first year due to the burden of frequent injections.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.